Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Alterity Therapeutics Ltd in metadata) covers the month of September 2016. The document serves as a report of a foreign private issuer and incorporates by reference the company's Corporate Governance Statement for the financial year ended June 30, 2016. The filing primarily consists of Appendix 4G, a key to disclosures regarding the company's adherence to the ASX Corporate Governance Council Principles and Recommendations.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The document is strictly a governance compliance report and does not contain financial statements or performance metrics for the period.
Material Changes
No material financial changes or operational updates are disclosed in this specific filing. The document confirms that the Corporate Governance Statement is accurate and up to date as of June 30, 2016, and approved by the board.
Guidance, Outlook, and Governance Disclosures
The filing details the company's compliance status with ASX Corporate Governance Council recommendations:
- Compliance Status: Prana Biotechnology Limited indicates it has followed most recommendations in full for the reporting period.
- Non-Compliance/Deviations:
- Principle 2.5: The company has not followed the recommendation that the Chair of the Board be an independent director and not the same person as the CEO. An explanation for this deviation is provided in the Corporate Governance Statement.
- Principle 7.1: The company does not have a dedicated risk committee satisfying the specific membership requirements. Instead, the board employs alternative processes for overseeing the risk management framework.
- Committees: The company confirms the existence of a Nomination Committee, Audit Committee, and Remuneration Committee, with charters available on their investor website.
- Internal Audit: The filing indicates the company does not have an internal audit function but employs processes to evaluate risk management and internal controls.
Investor Verification Checklist
- Verify the specific explanation for the deviation from Principle 2.5 (Chair/CEO independence) in the full Corporate Governance Statement (Pages 48-56 of the Annual Report).
- Review the alternative risk management processes described in the Corporate Governance Statement, given the absence of a formal risk committee.
- Confirm the company's financial position and cash runway by reviewing the full Annual Report for the year ended June 30, 2016, as this 6-K contains no financial data.
- Check the company website (http://pranabio.com/investors/) for the full text of committee charters and the diversity policy.